Cranium AI and ISTARI Forge Global Alliance to Drive Enterprise AI Security and Governance
21.5.2026 12:00:00 CEST | Business Wire | Press Release
Cranium AI, the leading end-to-end AI Security and Governance platform, and ISTARI, a leading cyber resilience advisory firm, today announced a strategic partnership to provide global organizations with an end-to-end AI security & governance solution.
As organizations accelerate AI adoption, they face a critical challenge: implementing actionable, operational AI governance while keeping pace with the speed of the AI landscape. This collaboration bridges that gap by merging Cranium’s cutting-edge AI security and governance platform with ISTARI’s deep advisory expertise in cyber risk and operating model design. Together, the firms provide a powerful, end-to-end solution for enterprises navigating the complexities of AI transformation.
A Unified Vision for Sustainable AI Governance
The partnership is built on a shared mission to move organizations beyond fragmented AI initiatives toward fully operationalized, secure, and governed programs. By combining Cranium’s platform automation with ISTARI’s advisory-led execution, AI security becomes a sustainable operational capability rather than a standalone tool.
The joint approach delivers:
- Automated Discovery and Testing: Cranium AI provides automated discovery, security testing, and real-time compliance monitoring across internal and third-party AI systems.
- Embedded Governance: ISTARI ensures these technical capabilities are woven into enterprise processes, governance frameworks, and operating models.
- Regulatory Alignment: Together, the firms help clients identify and mitigate AI-specific risks while operationalizing governance aligned with emerging regulations.
- Enterprise Integration: The partnership integrates AI security directly into existing enterprise workflows, reducing manual effort and enhancing real-time, data-driven decision-making for executives.
Executive Perspective
“Enterprises today don’t just need visibility into their AI—they need the ability to secure and govern it at scale,” said Jonathan Dambrot, CEO and Co-founder of Cranium AI. “This partnership with ISTARI ensures that Cranium’s platform is not only deployed but truly embedded into how organizations operate. Together, we are enabling clients to move from awareness to action, with AI security built into every phase of their journey.”
Rossa Shanks, CEO of ISTARI, added: “Enterprises are deploying AI faster than they can govern it, and the gap between ambition and assurance is where risk now lives. Our partnership with Cranium brings together their unified AI security and governance platform with ISTARI's advisory expertise and global network of senior practitioners, giving boards and CISOs a credible path from principle to practice. This is what cyber stewardship of AI looks like in execution.”
About Cranium AI
Cranium AI is the leading end-to-end AI Security and Governance platform, helping enterprises secure and govern their AI across the full model lifecycle. Headquartered in the New York metropolitan area, Cranium is committed to the mission of making AI safe and trustworthy for everyone, driven by a team of "Craniacs" who are redefining the standards for AI excellence with value realization.
For more information, visit www.cranium.ai or follow us on LinkedIn.
About ISTARI
ISTARI is a global cybersecurity firm, established by Temasek in 2020, with a unique model for helping clients build cyber resilience. Our mission is to help organisations achieve lasting cyber resilience with a whole-of-company approach, by leveraging peerless talent, expertise, and innovation through an unparalleled network. Our vision is to curate the defining cyber resilience ecosystem of our time - uniting academia, enterprise, practitioners, policymakers, and innovators to outpace cyber risk and build collective resilience.
For more information, visit www.istari-global.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260521886801/en/
Contacts
Media Contacts
Cranium AI:
Betsy J. Walker
Email: bwalker@cranium.ai
ISTARI:
Ellie Watmuff, Global Marketing Director
Email: elliewatmuff@istari-global.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom